Net sales nearly doubled year-over-year, driven by organic growth and acquisitions, with improved EBITDA and gross margin. European expansion accelerated with new launches and distribution agreements, while the Cerevia platform advanced toward commercialization.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.